Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer

M. G. Kris, Richard J. Gralla, M. S. Wertheim, D. P. Kelsen, J. P. O'Connell, M. T. Burke, J. J. Fiore, I. R. Cibas, R. T. Heelan

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

In prior trials, mitomycin, vindesine, and cisplatin have each been shown to have reproducible antitumor activity as single agents when used in the treatment of patients with non-small cell lung cancer. The two-drug combinations of vindesine plus high-dose cisplatin or mitomycin have shown an improved major response rate and manageable toxicity in prior trials. In this report, 90 patients with stage III non-small cell lung cancer were treated with the three-drug combination of mitomycin (8 mg/m2), vindesine (3 mg/m2), and high-dose cisplatin (120 mg/m2). Eighty-seven patients (97%) were adequate for both response and toxicity. Major objective responses occurred in 60% of the patients. The toxicity of this regimen was predictable and manageable when established supportive care measures were employed. Based on the response rate observed, the combination of these three agents merits further study in randomized trials against other chemotherapeutic regimens and consideration of its use in adjuvant and preoperative settings.

Original languageEnglish (US)
Pages (from-to)1091-1096
Number of pages6
JournalCancer Treatment Reports
Volume70
Issue number9
StatePublished - 1986
Externally publishedYes

Fingerprint

Vindesine
Mitomycin
Non-Small Cell Lung Carcinoma
Cisplatin
Drug Combinations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kris, M. G., Gralla, R. J., Wertheim, M. S., Kelsen, D. P., O'Connell, J. P., Burke, M. T., ... Heelan, R. T. (1986). Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer. Cancer Treatment Reports, 70(9), 1091-1096.

Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer. / Kris, M. G.; Gralla, Richard J.; Wertheim, M. S.; Kelsen, D. P.; O'Connell, J. P.; Burke, M. T.; Fiore, J. J.; Cibas, I. R.; Heelan, R. T.

In: Cancer Treatment Reports, Vol. 70, No. 9, 1986, p. 1091-1096.

Research output: Contribution to journalArticle

Kris, MG, Gralla, RJ, Wertheim, MS, Kelsen, DP, O'Connell, JP, Burke, MT, Fiore, JJ, Cibas, IR & Heelan, RT 1986, 'Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer', Cancer Treatment Reports, vol. 70, no. 9, pp. 1091-1096.
Kris MG, Gralla RJ, Wertheim MS, Kelsen DP, O'Connell JP, Burke MT et al. Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer. Cancer Treatment Reports. 1986;70(9):1091-1096.
Kris, M. G. ; Gralla, Richard J. ; Wertheim, M. S. ; Kelsen, D. P. ; O'Connell, J. P. ; Burke, M. T. ; Fiore, J. J. ; Cibas, I. R. ; Heelan, R. T. / Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer. In: Cancer Treatment Reports. 1986 ; Vol. 70, No. 9. pp. 1091-1096.
@article{84c71f0c201f424e830a5940539cdb5b,
title = "Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer",
abstract = "In prior trials, mitomycin, vindesine, and cisplatin have each been shown to have reproducible antitumor activity as single agents when used in the treatment of patients with non-small cell lung cancer. The two-drug combinations of vindesine plus high-dose cisplatin or mitomycin have shown an improved major response rate and manageable toxicity in prior trials. In this report, 90 patients with stage III non-small cell lung cancer were treated with the three-drug combination of mitomycin (8 mg/m2), vindesine (3 mg/m2), and high-dose cisplatin (120 mg/m2). Eighty-seven patients (97{\%}) were adequate for both response and toxicity. Major objective responses occurred in 60{\%} of the patients. The toxicity of this regimen was predictable and manageable when established supportive care measures were employed. Based on the response rate observed, the combination of these three agents merits further study in randomized trials against other chemotherapeutic regimens and consideration of its use in adjuvant and preoperative settings.",
author = "Kris, {M. G.} and Gralla, {Richard J.} and Wertheim, {M. S.} and Kelsen, {D. P.} and O'Connell, {J. P.} and Burke, {M. T.} and Fiore, {J. J.} and Cibas, {I. R.} and Heelan, {R. T.}",
year = "1986",
language = "English (US)",
volume = "70",
pages = "1091--1096",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer

AU - Kris, M. G.

AU - Gralla, Richard J.

AU - Wertheim, M. S.

AU - Kelsen, D. P.

AU - O'Connell, J. P.

AU - Burke, M. T.

AU - Fiore, J. J.

AU - Cibas, I. R.

AU - Heelan, R. T.

PY - 1986

Y1 - 1986

N2 - In prior trials, mitomycin, vindesine, and cisplatin have each been shown to have reproducible antitumor activity as single agents when used in the treatment of patients with non-small cell lung cancer. The two-drug combinations of vindesine plus high-dose cisplatin or mitomycin have shown an improved major response rate and manageable toxicity in prior trials. In this report, 90 patients with stage III non-small cell lung cancer were treated with the three-drug combination of mitomycin (8 mg/m2), vindesine (3 mg/m2), and high-dose cisplatin (120 mg/m2). Eighty-seven patients (97%) were adequate for both response and toxicity. Major objective responses occurred in 60% of the patients. The toxicity of this regimen was predictable and manageable when established supportive care measures were employed. Based on the response rate observed, the combination of these three agents merits further study in randomized trials against other chemotherapeutic regimens and consideration of its use in adjuvant and preoperative settings.

AB - In prior trials, mitomycin, vindesine, and cisplatin have each been shown to have reproducible antitumor activity as single agents when used in the treatment of patients with non-small cell lung cancer. The two-drug combinations of vindesine plus high-dose cisplatin or mitomycin have shown an improved major response rate and manageable toxicity in prior trials. In this report, 90 patients with stage III non-small cell lung cancer were treated with the three-drug combination of mitomycin (8 mg/m2), vindesine (3 mg/m2), and high-dose cisplatin (120 mg/m2). Eighty-seven patients (97%) were adequate for both response and toxicity. Major objective responses occurred in 60% of the patients. The toxicity of this regimen was predictable and manageable when established supportive care measures were employed. Based on the response rate observed, the combination of these three agents merits further study in randomized trials against other chemotherapeutic regimens and consideration of its use in adjuvant and preoperative settings.

UR - http://www.scopus.com/inward/record.url?scp=0022461326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022461326&partnerID=8YFLogxK

M3 - Article

C2 - 3527408

AN - SCOPUS:0022461326

VL - 70

SP - 1091

EP - 1096

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 9

ER -